# Takeda: Phase 2 study completed, 324 enrolled (Carcinoma, Non-Small-Cell Lung)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Takeda |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer |
| NCT ID | NCT02716116 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention types | drug |
| Target enrollment | 324 |
| Site countries | United States, China, Germany, Italy, Japan, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom |
| Posted | 2016-03-23 |
| Planned start | 2016-06-16 |
| Event | Completed |
| Event date | 2026-09-29 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 324 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT02716116). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.